- Article
Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells
- María José López-Grueso,
- Raúl González,
- Jordi Muntané,
- José Antonio Bárcena and
- C. Alicia Padilla
Sorafenib is the first-line recommended therapy for patients with advanced hepatocarcinoma (HCC) in de-differentiation stage (presenting epithelial–mesenchymal transition, EMT). We studied the role of the thioredoxin system (Trx1/TrxR1) in the...

